Nishimura T, Takeda M, Nakamura Y, Yosbida Y, Arai H, Sasaki H, Shouji M, Hirai S, Khise K, Tanaka K, Hamamoto M, Yamamoto H, Matsubayashi T, Urakami K, Adachi Y, Nakashima K, Toji H, Nakamura S, Yoshida H
Department of Human and Cultural Science, Koshien University, Japan.
Methods Find Exp Clin Pharmacol. 1998 Apr;20(3):227-35.
The development of a diagnostic marker for earlier and more accurate clinical diagnosis of Alzheimer's disease (AD) is essential to identify AD patients during life unequivocally. The purpose of this study was to investigate the basic performance and clinical significance of tau level measurement in the cerebrospinal fluid (CSF) using an enzyme-linked immunosorbent assay (ELISA) developed by Innogenetics. The ELISA system showed reliable reproducibility and good linearity. For clinical studies, the CSF samples from a variety of patients (n = 332) were examined. They were classified into the four groups: Alzheimer's disease (AD); neurodegenerative disease (ND); cerebrovascular diseases (VD); and a neurological control (NC) group. The CSF-tau levels for AD, ND, VD and NC were 426 +/- 234 pg/ml, 239 +/- 157 pg/ml, 216 +/- 136 pg/ml, and 188 +/- 103 pg/ml, respectively. The CSF-tau level of the AD group was significantly higher than that of the other groups (p < 0.001). The CSF-tau levels increased during follow-up. The measurement of the tau level in CSF is shown to be a useful marker to confirm a clinical diagnosis of AD.
开发一种用于阿尔茨海默病（AD）早期更准确临床诊断的诊断标志物对于明确在患者生前识别AD患者至关重要。本研究的目的是使用Innogenetics开发的酶联免疫吸附测定（ELISA）法研究脑脊液（CSF）中tau水平测量的基本性能和临床意义。该ELISA系统显示出可靠的重复性和良好的线性。对于临床研究，检测了来自各类患者（n = 332）的CSF样本。他们被分为四组：阿尔茨海默病（AD）组；神经退行性疾病（ND）组；脑血管疾病（VD）组；以及神经学对照组（NC）。AD、ND、VD和NC组的CSF-tau水平分别为426±234 pg/ml、239±157 pg/ml、216±136 pg/ml和188±103 pg/ml。AD组的CSF-tau水平显著高于其他组（p < 0.001）。随访期间CSF-tau水平升高。CSF中tau水平的测量被证明是确认AD临床诊断的有用标志物。
